In this study, we found that DCs, loaded with this new MUC1-Vax immunogen can induce the body to continuously produce anti-PD-L1 antibodies, which can inhibit the binding of PD-L1 on tumor cells and PD-1 on T cells, thus relieving the inhibition of tumor cells on T cells to a certain extent and releasing part of T cells. Here, CD274 is linked to neoplasm.